Trial · NCT07335588
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Achieving IGA-LS TS at Week 12 | Week 12 | |
| Secondary | Number of Participants Achieving IGA-LS TS at Week 8 | Week 8 | |
| Secondary | Change in Clinical Lichen Sclerosus Score (CLISSCO) from Baseline to Week 12 | Baseline to Week 12 | |
| Secondary | Number of Participants Achieving a Reduction of Skin Pain Numerical Rating Scale (NRS) Score (Weekly Average) of ≥4 Points from Baseline to Week 12 in Participants with Baseline Skin Pain NRS Score ≥4 | Baseline to Week 12 | |
| Secondary | Number of Participants Achieving a Reduction of Skin Pain NRS Score (Weekly Average) of ≥4 Points from Baseline to Week 8 in Participants with Baseline Skin Pain NRS Score ≥4 | Baseline to Week 8 | |
| Secondary | Number of Participants Achieving a Reduction of Itch NRS Score (Weekly Average) of ≥4 Points from Baseline to Week 12 in Participants with Baseline Itch NRS Score ≥4 | Baseline to Week 12 | |
| Secondary | Number of Participants Achieving a Reduction of Itch NRS Score (Weekly Average) of ≥4 Points from Baseline to Week 8 in Participants with Baseline Itch NRS Score ≥4 | Baseline to Week 8 | |
| Secondary | Change in Vulvar Quality of Life Index (VQLI) Score from Baseline to Week 12 | Baseline to Week 12 | |
| Secondary | Number of Participants Achieving IGA-LS TS at Week 52 | Week 52 | |
| Secondary | Change in CLISSCO Score from Baseline to Week 52 | Baseline to Week 52 | |
| Secondary | Number of Participants Achieving IGA-LS TS at Week 52 Among Participants Having Achieved IGA-LS TS at Week 12 | Week 52 | |
| Secondary | Number of Participants Achieving an IGA-LS Score of 0 or 1 at Week 52 Among Participants Having Achieved IGA-LS TS at Week 12 | Week 52 | |
| Secondary | Time to IGA-LS TS from Baseline to Week 52 | Baseline to Week 52 | |
| Secondary | Time to IGA-LS ≥2 from Week 12 to Week 52 Among Participants Having Achieved IGA-LS TS at Week 12 | Week 12 to Week 52 | |
| Secondary | Number of Participants Having no Increase in CLISSCO Architectural Changes Domain Score from Baseline to Week 52 | Baseline to Week 52 | |
| Secondary | Number of Participants Achieving a Reduction of Skin Pain NRS Score (Weekly Average) of ≥4 Points from Baseline to Week 52 in Participants with Baseline Skin Pain NRS Score ≥4 | Baseline to Week 52 | |
| Secondary | Number of Participants Achieving a Reduction of Itch NRS Score (Weekly Average) of ≥4 Points from Baseline to Week 52 in Participants with Baseline Itch NRS Score ≥4 | Baseline to Week 52 | |
| Secondary | Number of Treatment-emergent Adverse Events (TEAEs) from Baseline to Week 12 | Baseline to Week 12 | |
| Secondary | Number of TEAEs from Week 12 to Week 54 | Week 12 to Week 54 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07335588/registered